Article

Overview of Adverse Events Associated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy

2021-04-19

Abstract excerpt

Anti-CD19 chimeric antigen receptor (CAR) T-cells represent a novel immunotherapy that has shown remarkable success in the treatment of adult relapsed or refractory (R/R) B-cell non-Hodgkin's lymphoma, adult R/R mantle cell lymphoma, and R/R acute paediatric lymphoblastic leukaemia. One barrier to the widespread use of CAR T-cell therapy is toxicity, primarily cytokine release syndrome (CRS) with a variable grade...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 79633dda-8588-50f4-8901-6841add59b85
DOI: 10.20944/preprints202104.0517.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Overview of Adverse Events Associated With Anti-CD19 Chimeric Antigen Receptor T-Cell TherapyDOI 10.20944/preprints202104.0517.v1Read

Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to managementSemantic proximity Read

Prolonged Cytopenia with CAR-T Cell Therapy and Management RecommendationsSemantic proximity Read

Chimeric Antigen Receptor‐T Cell TherapySemantic proximity Read

Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic LeukemiaSemantic proximity Read

Marker genes for predicting cytokine release syndrome in vitro before CAR T cell infusionSemantic proximity Read

Interferon-γ blockade in CAR T-cell therapy–associated macrophage activation syndrome/hemophagocytic lymphohistiocytosisSemantic proximity Read

Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignanciesSemantic proximity Read

Marker genes for predicting cytokine release syndrome in vitro before CAR T cell infusionSemantic proximity Read

Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell MalignanciesSemantic proximity Read

Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphomaSemantic proximity Read

Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational studySemantic proximity Read

Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factorsSemantic proximity Read